Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. announced a settlement agreement with Aurobindo Pharma Limited resolving patent litigation concerning generic versions of NEXLETOL and NEXLIZET. Under the agreement, Aurobindo will not market generic versions of these drugs in the U.S. before April 19, 2040, unless certain conditions are met. The company's patent litigation against other defendants, including MSN Pharmaceuticals Inc. and Sandoz Inc., remains active. Esperion is a biopharmaceutical company developing and commercializing therapies for cardiometabolic and rare/orphan diseases.

Esperion Therapeutics, Inc. entered into a Contingent Value Rights (CVR) Agreement, granting holders rights to up to $100 million based on specified milestones, following its merger. A Second Supplemental Indenture was also executed, modifying the terms of its 5.75% Convertible Senior Subordinated Notes due 2030, converting them into cash and CVRs due to a Make-Whole Fundamental Change. Additionally, the company secured a new Loan Agreement and repaid all outstanding obligations under a previous agreement.

Esperion Therapeutics announced that the Hart-Scott-Rodino Antitrust Improvements Act waiting period for its merger with Essence Parent Inc. expired on June 15, 2026. This marks a key step towards completing the acquisition, which was initially disclosed on May 1, 2026. The merger remains subject to other customary closing conditions, including approval by Esperion's stockholders at a special meeting scheduled for July 8, 2026.

Esperion Therapeutics announced that the Bundeskartellamt, the German antitrust authority, has cleared its previously disclosed merger with Essence Parent Inc., an affiliate of ArchiMed SAS. This clearance, effective June 2, 2026, satisfies one of the key conditions for the merger. The completion of the merger is still contingent upon other closing conditions, including the expiration of waiting periods under the Hart-Scott-Rodino Antitrust Improvement Act and the adoption of the Merger Agreement by Esperion's stockholders at a meeting scheduled for July 8, 2026.

Esperion Therapeutics, Inc. held its 2026 annual meeting of stockholders on May 28, 2026. Key outcomes included the approval of an amendment to the 2022 Stock Option and Incentive Plan, increasing the aggregate number of shares authorized for issuance by 7,000,000. Stockholders also elected two Class I directors, approved the non-binding advisory resolution on executive compensation, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Esperion Therapeutics announced positive results from a Phase 2 study of bempedoic acid in children with familial hypercholesterolemia, showing LDL-C reduction and good tolerability. Additionally, a post hoc analysis from the CLEAR Outcomes trial identified patient factors, including female sex and higher baseline LDL-C, associated with a 30% or greater reduction in LDL-C in statin-intolerant adults. These data were presented at the European Atherosclerosis Society (EAS) Congress 2026, supporting the broad utility of bempedoic acid.

Esperion Therapeutics announced that it granted 260,000 restricted stock units (RSUs) to 23 new employees on May 12, 2026. These grants were made under the Company's 2017 Inducement Equity Incentive Plan, which is used to attract new talent as an inducement for employment. The RSUs will vest over time, with 25% vesting on the one-year anniversary and the remaining 75% in twelve equal quarterly installments, contingent on continued employment.

Esperion Therapeutics announced an agreement to be acquired by Essence Parent Inc. for $3.16 per share in cash plus one contingent value right (CVR) per share, potentially adding up to $100 million in aggregate upon milestone achievement. This merger is expected to close in Q3 2026. Separately, Esperion completed the acquisition of Corstasis Therapeutics Inc. for $75 million upfront cash, expanding its cardiovascular portfolio with Enbumyst. For Q1 2026, total revenues increased to $80.1 million from $65.0 million year-over-year, while net loss decreased to $25.2 million from $40.5 million.

Esperion Therapeutics announced a definitive agreement to be acquired by ARCHIMED, a healthcare investment firm, in a transaction valued at up to approximately $1.1 billion in total equity value. Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium to the April 30, 2026 closing price. Additionally, shareholders will receive contingent value rights for up to $100 million in aggregate milestone payments tied to future net sales performance of its core cardiometabolic products. The transaction is expected to close in the third quarter of 2026, after which Esperion will become a privately held company.

Esperion Therapeutics, Inc. announced it will report its first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these results and provide business updates. A live audio webcast will be accessible on the company's investor and media section, with a replay available for approximately 90 days.